Global Adrenogenital Syndrome Treatment Market for Growth, Projected to Reach US$ 22.08 Billion at a 5.6% CAGR by 2033

Adrenogenital Syndrome Treatment Market
Adrenogenital Syndrome Treatment Market

The global adrenogenital syndrome treatment market is anticipated to grow at a compound annual growth rate (CAGR) of 5.6% from 2023 to 2033, with a projected value of US$ 12.81 billion. Growth is anticipated to be fueled by novel therapies, minimally invasive operations, and natural remedies.

In Austria, newborn screening programs are designed to identify severe cases of AGS so that the afflicted children can be appropriately treated to prevent potentially fatal salt-wasting crises. One of the therapies offered as part of newborn screening programs is swap therapy. Since the symptoms of lesser variants, also known as non-classical AGS, manifest later in life and are less severe than those of classical AGS, they may go unnoticed for an extended period of time.

Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16420

It is anticipated that surgical correction of aberrant genital looks will further boost the market. The hormones that the adrenal glands are unable to produce are also replaced by hormonal therapy. Patients with long-term atopic illnesses are prescribed hydrocortisone or corticosteroids on a regular basis. The course of this medication is expected to normalize testosterone production.

Market Competition:

Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demands. To ensure that end users are able to benefit from the use of new products and technologies, you must promote them to end users. By forming a strategic partnership, a company can increase the amount of production it can do as a result of an increase in its capacity.

  • Spruce Biosciences Inc. and Kaken Pharmaceutical Co. Ltd announced a licensing agreement to develop and commercialize Spruce’s product candidate, tildacerfont, for treating congenital adrenal hyperplasia (CAH). Spruce will receive a $15 million upfront payment from Kaken as part of the agreement, and additional payments are pending upon reaching future development and commercial milestones. In addition to that, tiers of double-digit royalties will be paid on Japanese net sales. For all other geographies, Spruce will retain all rights to tildacerfont, while Kaken will develop and market it in Japan.
  • A new Phase 2 study from Neurorocrine Biosciences, Inc. is being presented demonstrating substantial reductions in adrenal androgens and androgen precursors in adolescent patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD). As part of its presentation in Hall A1, the company also provided information regarding patient preferences and treatment patterns for classic CAH.

Explore Our Methodology Framework:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16420

Key Companies Profiled:

  • Crystal Pharma
  • Monarch Pharmaceuticals, Inc.
  • Jubilant Cadista Pharmaceuticals Inc.
  • Pfizer CentreOne
  • Healthkey Lifescience Pvt. Ltd.
  • Zydus Pharmaceuticals
  • Praxgen Pharmaceuticals
  • Sandoz
  • Vintage Labs
  • Actavis, Inc.

Key Segments Profiled in the Adrenogenital Syndrome Treatment Market Industry Survey:

By Drug Type:

  • Mineralocorticoids
  • Glucocorticoids

By Route of Administration:

  • Oral
  • Parenteral
  • Intravenous
  • Inhaled
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Detailed Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16420

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these